Think Research Reports Q2 and First Half 2022 Results, Highlighted by Strong Revenue Growth and Continued Cost Synergies
Retrieved on:
Monday, August 29, 2022
Software, Depreciation, COVID-19, Mission statement, Research, CEO, EBITDA, Government, Achievement, Solution, Pharmacy, Net income, IFRS, Arbutus Biopharma, Beedi, Conversation, Intelligence, Organization, Indian stock exchange, Company, Convertible, Nursing, SEDAR, Acquisition, Growth, Leonora O'Brien, Marketing, Patient, Pharmaceutical industry, Video game, Renewable energy, Bank, Security (finance), Thought
Further, Think is increasingly winning larger deals and we are confident that our current trajectory is aligned with the Company's near and longer-term growth and profitability expectations."
Key Points:
- Further, Think is increasingly winning larger deals and we are confident that our current trajectory is aligned with the Company's near and longer-term growth and profitability expectations."
- Subsequent to the quarter-end, Think was able to recognize parts of the delayed revenue and anticipates that this segment will experience a recovery in revenue in the latter part of the second half.
- Adjusted EBITDA Margin2(as defined herein) was negative 9% in Q2 compared to negative 13% in Q2 2021.
- Think also made payments of $1.6 million on lease liabilities and $1.6 million for finance costs in the first half of 2022.